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Abstract
OBJECTIVE: To investigate whether cancer stem
cells (CSCs) more efficiently activating platelets and
evading immune surveillance than non-CSCs thus
promoting metastasis.
METHODS: We enriched and identified sphere-
forming cells (SFCs) and coincubated washed plate-
lets with several platelet activators including colla-
gen, 4T1 and SFCs. Platelet-coating tumor cells,
platelet activation and TGF-β1 release were ana-
lyzed. Then natural kell cells (NK) were incubated
with supernatants of different activated platelet
samples what we called sample release (SR). The de-
granulation assay and NKG2D expression on NK
cells were conducted by flow cytometry. Finally tis-
sue factor (TF) expression of SFCs or 4T1 were eval-
uated by western blot.
RESULTS: Breast cancer cell line 4T1 could form
spheres in serum-free medium at low adherence.
Sphere-forming cells expressed high levels of the
CD24-/lowCD44 + stem cell phenotype. Both
sphere-forming cells or 4T1 were coated with abun-
dant platelets while sphere-forming cells induced
significantly higher expression of platelet activat-
ing receptor CD62p than 4T1 did (P < 0.01). And
sphere-forming cells induced platelets to produce
more TGF-β1 than 4T1 did (P < 0.01). Furthermore,
sample releases induced by sphere-forming cells
caused more vigorous inhibition of NK cells antitu-
mor reactivity (P < 0.05) and reduced NKG2D ex-
pression (P < 0.01). The final results showed that
sphere-forming cells expressed higher levels of TF
than 4T1 (P < 0.05).
CONCLUSION: Our findings indicate that CSCs
could efficiently activate platelets, induce platelets
to secrete more TGF-β1, decrease NKG2D expres-
sion and inhibit antitumor activity of NK cell, com-
pared with 4T1. And higher levels of TF expression
of CSCs may account for this correlation of CSCs
and platelets.
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INTRODUCTION
Metastasis is the primary cause of cancer treatment fail-
ure and patient death. Understandings of Traditional
Chinese Medicine (TCM) for tumor metastasis began
from Qin and Han dynasties,1 of which TCM "Fudu"
theory2 was an important one. The theory holds that
"Fudu" is a kind of delitescent pathogenic Qi remained
after cancer treatment such as surgery, radiotherapy or
chemotherapy. The residual pathogenic Qi cannot be
eliminated by deficient Qi and accumulates to generate
the pathogenic factor "Fudu". It may spread to other
parts of the body and forms a new one.2 On the other
hand, with the progress of stem cell biology and the
deepening of pathogenesis of cancer research in recent
years, accumulating evidence suggests that not all tu-
mor cells metastasize, but a small part of cancer stem
cells (CSCs) with stem-like properties determine tu-
mor recurrence and metastasis.3 CSCs are usually in a
relatively static state and able to successfully escape de-
struction of radiochemotherapy, thus become the
source of tumor metastasis.4-6 It elucidates that "Fudu"
theory is very similar to modern medicine understand-
ings of tumor metastasis by CSCs. Moreover, TCM
therapeutic method "Fuzheng Qudu" (strengthening
body resistance and dispelling toxicity) for tumor,
based on "Fudu" theory, is clinically proven to have ef-
fects on tumor metastasis.7,8
According to "Fudu" theory, "Fudu" differs from gener-
al pathogenic Qi and has greater ability to transfer
along channels and blood vessels.2 Modern medicine al-
so focuses on the issue how tumor cells leave the prima-
ry tumor, invade into blood vessels and travel to other
parts of the body to finally generate metastatic tumors.
Numerous studies show that platelets could promote
tumor progression and metastasis.9,10 After tail vein in-
jection of tumor cells in mice with thrombocytopenia,
their pulmonary metastases decreased which could be
reversed by platelet transfusion.11 In vivo and vitro stud-
ies reveal that thrombocytopenia could reduce tumor
cell spread, which may be due to destruction of nature
killer (NK) cells.12-15 Thus, platelets would adhere to tu-
mor cells by which platelet-tumor cell interaction
caused platelet activation and release of platelet granule
contents, and finally tumor cells with help of platelets
escaped immune surveillance and elimination.9 This
raises the question whether CSCs, as the origin of me-
tastasis, may be more effective to active platelets and
evade immune surveillance than non-CSCs? It
prompts us to explore the mechanisms of CSCs giving
rise to tumor metastasis from the perspective of CSCs,
platelets and NK cells.
MATERIALS ANDMETHODS
Animal and cell
Female BALB/c mice, weighted 19 to 21g, were pur-
chased from Beijing Charles River Laboratory Animal
Technology Co., Ltd., [certification No. SCXK (Jing)
2012-0001] (Beijign, China) and fed in the Laboratory
Animal Center of Guangan'men Hospital. The tumor
cell line 4T1 (breast cancer cell) was so kindly sent us
by Laboratory of Molecular Immunology Adjustment,
National Cancer Institute.
Reagents
Anti-CD24-PE, anti-CD44-APC, Anti-CD61-PE, An-
ti-CD62p-FITC, Anti-CD49b-FITC, Anti-CD107a-
APC, Anti-CD314-PE were perchased from BD
(Franklin Lakes, NJ USA) together with the corre-
sponding isotype controls. Anti-CD41 antibody, An-
ti-Tissue Factor antibody, Anti-beta Actin antibody
and Goat Anti-Rabbit IgG H & L (FITC) were from
Abcam (Cambridge, UK). Mouse Spleen Mononuclear
Cell Isolation Kit was from TBD (Tianjin, China). Pro-
tein Transport Inhibitor (Containing Monensin) was
from BD (Franklin Lakes, NJ, USA). Mouse TGF-β1
ELISA kits was from R & D (Minneapolis, MN,
USA). Goat Anti-Rabbit IgG H & L (HRP) was from
Jackson (Baltimore Pike, MD, USA).
Cell culture and tumor sphere enriching
Grown were 4T1in RPMI-1640 medium containing
10% fetal bovine serum (FBS), penicillin and strepto-
mycin at 37 ℃ in a 5% CO2 incubator. 4T1 in loga-
rithmic growth phase (passage 5-8) were cultured in se-
rum-free DMEM/F12 medium supplemented with
10 ng/mL human recombinant basic fibroblast growth
factor (bFGF), 20 ng/mL human recombinant epider-
mal growth factor (EGF), 1∶50 B27, 5 μg/mL insulin,
0.4% BSA, 2% KnockOut, l% penicillin and strepto-
mycin in Ultra-Low Attachment 6-Well Plates. After
5-7 days, Tumor spheres were collected by centrifugat-
ing at 1000 rpm for 5 min, detached enzymatically in
0.25% trypsin (0.02% EDTA) and cultivated in the
same medium to generate tumor spheres of the next
generation.
Preparation of mouse washed platelets and spleen
mononuclear cells
Washed platelets were extracted and prepared follow-
ing general method described previously.16-18 latelets
were obtained by cardiac puncture. Citrated blood was
diluted with 250 μL of modified Tyrodes-HEPES buf-
fer (134 mmol/L NaCl, 0.34 mmol/L Na2HPO4,
2.9 mmol/L KCL, 12 mmol/L NaHCO3, 20 mmol/L
HEPES, 5 mmol/L glucose, 1 mmol/L MgCl2, PH
7.3) and centrifuged at 120 × g for 20 min. Plate-
let-rich plasma (PRP) was obtained, and the rest of
blood was centrifuged at 800 × g for 10 min to remove
platelet-poor plasma (PPP). PRP was subsequently cen-
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trifuged by adding 0.1 μg/mL prostacyclin at 1000 × g
for 5 min. Pelleted platelets were suspended in RP-
MI-1640 medium (10% FBS). Washed platelets were
prepared and adjusted at a final concentration of 3 ×
104/uL using the hematology analyzer (Nihon kohden,
Tokyo, Japan). Spleen mononuclear cells were isolated
from mouse spleen using the Mouse Spleen Mononu-
clear Cell Isolation Kit.
Coating of tumor cells
Cuvettes with washed platelet suspension were put into
an platelet aggregometer (Chrono-log, Havertown, PA,
USA). Then different platelet activators were added in-
cluding 1 μg/mL collagen (Chrono-log, Havertown,
PA, USA) or 4T1 of 3 × 105/mL, or sphere-forming
cells (SFCs) of 3 × 105/mL with 5% platelet-poor plas-
ma. All platelet suspensions were stirred at 1000 rpm
for 10 min which served as distinct activated platelet
samples.18 Later these samples were centrifuged at 13
000 rpm for 15 min to collect the supernatants what
we called sample release (SR).
Immunofluorescence
Activated platelet samples by 4T1 or sphere-forming
cells were prepared for immunofluorescence as previ-
ously described.18 In a nutshell, anti-CD41 antibody
was incubated overnight at 4 ℃ . After successive PBS
washes, sections were incubated in FITC anti-rabbit
secondary antibodies and counterstained with 4,6-di-
amidino-2-phenylindole (DAPI) afterwards.
Flow cytometry
Flow cytometry was used in the identification of
sphere-forming cells, the activation of tumor cell-coat-
ing platelets, the degranulation assay and NKG2D ex-
pression on NK cells. Cells were incubated with desig-
nated antibodies or relevant isotype control on a Flow
Cytometer (Beckman Coulter, Brea, CA, USA). Mea-
surements are calculated as a percentage except for
NKG2D expression which is shown as specific fluores-
cence index (SFI): median fluorescence of designated
antibodies / median fluorescence of isotype control.
In particular, the degranulation assay of NK cells were
conducted as previously described.19,20 Mononuclear
cells were resuspended at 106 cells/mL in RPMI-1640
medium supplemented with 10% FBS, 2 mmol/L lglu-
tamine, 50 IU/mL penicillin. Cells were stimulated
with sphere-forming cells or 4T1 with an effector-tar-
get ratio of 3∶1 for 2 h at 37 ℃ in 5% CO2. Cells sus-
pensions were then added CD107a-APC antibody at
20 μL/mL and incubated for 1 h at 37 ℃ in 5% CO2.
Subsequently monensin was added according to the in-
structions and incubated for 5 h at 37 ℃ in 5% CO2.
Finally mononuclear cells were counterstained by NK
cell surface marker CD49b for 30 min. After washing,
cells were resuspended in PBS and analyzed by flow cy-
tometry.
ELISA
TGF-β1 levels were analyzed using ELISA kits accord-
ing to the instructions. All concentrations are expressed
as mean ± standard deviation in triplicate.
Western blotting
Sphere-forming cells and 4T1 were lysed to extract the
totle protein. The totle protein was seperated by means
of sodium dodecyl sulfate polyacrylamide gel electro-
phoresis (SDS-PAGE), and then transfered to polyvi-
nylidene difluoride (PVDF) membranes. Membranes
were blocked with blocking buffer containing 1g non-
fat-dried milk and 20 mL Tris buffered saline Tween
(TBST) for 1 h. And anti-tissue factor antibody (1∶
1000) was used to incubated membranes at 4 ℃ over-
night which were subsequently incubated by secondary
antibodies (1∶10 000) at room temperature for 1 h. Fi-
nally the images were analyzed by Gel Image System
Ver.4.00 (Tanon, Shanghai, China).
Statistical analysis
All data were presented as the mean ± standard devia-
tion. And statistical analyses were performed by
One-factor Analysis of Variance and Student's t test us-
ing SPSS (IBM, version 21.0, Armonk, NY, USA). P <
0.05 was considered significantly different.
RESULTS
Cultivation, propagation and identification of
sphere-forming cells
After 5-7 days 4T1 was inoculated into the medium
formed tumor spheres in which cells were tightly con-
nected to each other (Figure 1A). Tumor spheres could
be dissociated to passage several times, indicating that
they have self-renewal capacity. Our research group la-
beled tumor spheres of the third passage with an-
ti-CD24 and anti-CD44, and 4T1 cultured in se-
rum-supplemented medium served as control group.
The percentage of CD24-/lowCD44 + cells of
sphere-forming cells was significantly higher than that
of 4T1 (P < 0.01, Figure 1B).21
Sphere-forming Cells are more efficent to be coated
by activated platelets
After interacting with platelet, the expressions of plate-
let markers CD61 and CD62p were found on these
two tumor cells. And the expressions of CD62p in-
duced by sphere-forming cells or 4T1 were significant-
ly higher than that of collagen (P < 0.01). It's worth
noting that sphere-forming cells induced significantly
higher expression of CD62p than 4T1 did (P < 0.01,
Figure 2B and 2C).
Sphere-forming Cells induce platelets to secrete more
TGF-β1
So we detected the levels of TGF-β1 in different sam-
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ple releases. And the results showed that sample release
induced by sphere-forming cells contained a significant-
ly higher level of TGF-β1 than that of 4T1 (P < 0.01,
Figure 3). Consequently, sphere-forming cells induced
platelets to produce more TGF-β1 than 4T1 did.
Sphere-forming cells vigorously inhibit NK cell
antitumor reactivity
Sample releases induced by sphere-forming cells or
4T1 could reduce the expression of CD107a on NK
cells (P < 0.01; Figure 4A and 4B). Of particular note
was that preincubation of NK cells with sample releas-
es stimulated by sphere-forming cells caused a signifi-
cant decrease of CD107a than that by 4T1 (P < 0.05,
Figure 4C). These data show that sphere-forming cells
induced sample releases cause more vigorous inhibition
of NK cells antitumor reactivity. The natural killer
group 2 member D (NKG2D) represents a vital point
of immune response to cancer.22 Then we explored the
expression of this NK cell activating receptor to know
whether it may work in the inhibition of NK cells anti-
tumor reactivity. Again mononuclear cells were prein-
cubated with different sample releases overnight and
NKG2D expression was measured by flow cytometry.
Sample releases induced by sphere-forming cells (P <
0.01) or 4T1 (P < 0.05) could downregulate the
NKG2D expression on NK cells. And sphere-forming
cells had tendency to reduce more NKG2D expression
than 4T1 did, while there showed no significant differ-
ent (P >0.05, Figure 4D).
Sphere-forming cells expressed high levels of tissue
factor
Finally, to explore the molecular mechanism by which
sphere-forming cells efficiently induce platelets aggrega-
tion and activation, tissue factor (TF) levels of
sphere-forming cells and 4T1 were evaluated by west-
ern blotting analysis. Thus we found that sphere-form-
ing cells expressed higher levels of TF than 4T1 (P <
0.05, Figure 5).
DISCUSSION
Cancer stem cells, as a small group of cells in tumor,
have the self-renewal characteristic and ability to form
a variety of tumor cells of different lineages. Recent evi-
dences have shown the existence of CSCs in several
kinds of cancers such as brain, breast, prostate, pancre-
as, hepatobiliary, and colorectal cancer.23 Numerous in-
vestigators have enriched CSCs by sphere formation in
serum-free medium at low adherence.24,25 It also has
been reported to possess various properties including
extensive proliferation and tumorigenic ability, which
play pivotal roles in metastasis, the relapse of tumors
and resistance to therapies.26,27 However, few previous
studies have been preformed on the relationship and in-
teraction of CSCs, blood circulation and immune sys-
tem. Our study inspired by TCM "Fudu" theory clari-
fied that CSCs had a stronger effect on platelet activa-
tion, NK cell antitumor activity suppression and im-
mune surveillance evasion, compared with 4T1.
Researchers had been concerned about the correlation
and interaction between tumor and platelets from early
on. In 1872, Reiss and colleagues reported the associa-
tion of thrombocytosis and malignant disease.28 Then
Billroth further described tumor cells in blood clots of
cancer patients in 1878.29 Afterwards the study in mice
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Figure 1 4T1 can form tumor spheres with high expression of cancer stem cells phenotypes
A: 4T1 and tumor spheres (absolute original magnification, × 400). A1: 4T1 in serum-supplemented medium. A2: Tumor spheres
in serum-free medium. B: Flow cytometry analysis of CD24/CD44 expression in 4T1 and sphere-forming cells (SFCs). B1: 4T1. B2:
SFCs.
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model demonstrated that anticoagulant drugs made tu-
mor cells more susceptible to cytotoxicity of NK cells.
It indicated that platelet aggregation and coating of tu-
mor cells may be responsible for disseminating tumor
Figure 2 Tumor cells are efficently coated in platelet (PLT) aggregation
and activation
A: platelet-coated SFCs or 4T1 by immunofluorescence. Platelet mem-
branes were stained with CD41 (green). Nuclei were counterstained
with DAPI (blue). (absolute original magnification, × 400). A1-A3: Plate-
let-coated SFCs. A1: nuclei in SFCs group. A2: platelet membranes in
SFCs group. A3: merge image in SFCs group. A4-A6: Platelet-coated
4T1. A4: Nuclei in 4T1 group. A5: platelet membranes in 4T1 group.
A6: merge image in 4T1 group. B: CD61+CD62p+ cells by flow cytome-
try. B1: PLT group. B2: PLT+Collagen group. B3: PLT+4T1 group. B4:
PLT+SFCs group. For groups of PLT and PLT+Collagen, platelets were
gated by forward/side scatter characteristic; for groups of PLT + 4T1
and PLT+SFCs, platelet-coated tumor cells were gated. C: The relative
percentage of CD61+CD62p+ cells. aP﹤0.01, vs PLT. bP﹤0.01, vs PLT+
Collagen. cP﹤0.01, vs PLT+4T1. SFCS: sphere forming cells.
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cells by protecting them from NK cell mediated antitu-
mor activities.30 More lines of evidence suggested a po-
tential mechanism that tumor cells could stimulate
platelet activation and aggregation, impede NK cell
elimination, and transit within the blood stream.12-15
We have shown here that CSCs are efficiently coated
by platelets and have stronger effect on platelet activa-
tion. And sample release induced by CSCs more signifi-
cantly inhibited NK cell antitumor activity.
Then how was this platelet-CSCs interaction associat-
ed with NK cell antitumor activity? TGF-β1 derived
from platelet α-granule can diminish tumor metastasis
by decreasing NKG2D of NK cells.31 The regulatory
mechanisms of NK cells depend on the coordination
and balance of their membrane surface receptors. Tu-
mor cells escape immune surveillance by way of
down-regulation of NK cell activating receptors and
up-regulation of inhibitory receptors. And tumor cells
themselves can down-regulate the ligand of NK cell ac-
tivating receptors and up-regulate the ligand of inhibi-
tory receptors.32 Among these regulatory receptor, acti-
vating receptors NKG2D play a crucial role in the acti-
vation and antitumor activity of NK cells. Our study
further elucidate that sample release induced by CSCs
impair the NKG2D expression which result in antitu-
mor activity decline of NK cell. And more TGF-β1 re-
lease induced by CSCs may be responsible for the sig-
nificantly reduced NKG2D expression.
Finally why could CSCs activate platelets more effi-
ciently than 4T1? Evidences showed that TF extracellu-
lar domain was the receptor of coagulation factor FⅦ
and Ⅶa with the pro-coagulant activity which was the
key component to initiate the extrinsic coagulation
pathway. Tumor cells with high expression of TF could
activate the coagulation system and prompt fibrin gen-
eration and platelet aggregation. Thus tumor cells
wrapped within polymer of fibrin and platelets could
evade immune surveillance.33 CD133-positive A431
cells (CSCs) with high levels of TF had the increased
procoagulant activity relative to CD133-negative
cells.34 Our results also imply that CSCs have higher
levels of TF expression than 4T1 which may be bound
up with its better manifestation of inducing platelet ac-
tivation.
In conclusion, compared with 4T1, CSCs could effi-
ciently activate platelets, induce more TGF-β1 release,
decrease significantly NKG2D expression and restrain
antitumor activity of NK cells. Furthermore the prelim-
inary results indicate that higher levels of TF expres-
sion of CSCs may account for this correlation of CSCs
and platelets. Our study might provide further recogni-
tion for eliminating CSCs and improve therapeutic
method.
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Figure 5 Tissue factor (TF) expression of SFCs and 4T1
A: representative immunoblot of TF; 1: SFCs; 2: 4T1. B: quan-
tigication of the relative expression of TF. aP﹤0.05, vs SFCs.
SFC: sphere forming cells.
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